-
Je něco špatně v tomto záznamu ?
Implementation and Short-term Adverse Events of Anti-SARS-CoV-2 Vaccines in Inflammatory Bowel Disease Patients: An International Web-based Survey
P. Ellul, J. Revés, B. Abreu, M. Chaparro, JP. Gisbert, M. Allocca, G. Fiorino, B. Barberio, F. Zingone, A. Pisani, D. Cassar, G. Michalopoulos, G. Mantzaris, I. Koutroubakis, K. Karmiris, K. Katsanos, D. Ďuricova, J. Burisch, GR. Madsen, C....
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články
Grantová podpora
Portuguese Society of Gastroenterology
CEREGA
PubMed
35037033
DOI
10.1093/ecco-jcc/jjac010
Knihovny.cz E-zdroje
- MeSH
- COVID-19 * prevence a kontrola MeSH
- idiopatické střevní záněty * farmakoterapie MeSH
- internet MeSH
- lidé středního věku MeSH
- lidé MeSH
- průzkumy a dotazníky MeSH
- senioři MeSH
- vakcinace škodlivé účinky MeSH
- vakcíny proti COVID-19 * škodlivé účinky MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- senioři MeSH
- Publikační typ
- časopisecké články MeSH
- Geografické názvy
- Evropa MeSH
INTRODUCTION: Anti-SARS-CoV-2 vaccine clinical trials did not include patients with immune-mediated conditions such as inflammatory bowel disease [IBD]. We aimed to describe the implementation of anti-SARS-CoV-2 vaccination among IBD patients, patients' concerns, and the side effect profile of the anti-SARS-CoV-2 vaccines, using real-world data. METHODS: An anonymous web-based self-completed survey was distributed in 36 European countries between June and July 2021. The results of the patient characteristics, concerns, vaccination status, and side effect profile were analysed. RESULTS: In all 3272 IBD patients completed the survey, 79.6% had received at least one dose of anti-SARS-CoV-2 vaccine, and 71.7% had completed the vaccination process. Patients over 60 years old had a significantly higher rate of vaccination [p < 0.001]. Patients' main concerns before vaccination were the possibility of having worse vaccine-related adverse events due to their IBD [24.6%], an IBD flare after vaccination [21.1%], and reduced vaccine efficacy due to IBD or associated immunosuppression [17.6%]. After the first dose of the vaccine, 72.4% had local symptoms and 51.4% had systemic symptoms [five patients had non-specified thrombosis]. Adverse events were less frequent after the second dose of the vaccine and in older patients. Only a minority of the patients were hospitalised [0.3%], needed a consultation [3.6%], or had to change IBD therapy [13.4%] after anti-SARS-CoV-2 vaccination. CONCLUSIONS: Although IBD patients raised concerns about the safety and efficacy of anti-SARS-CoV-2 vaccines, the implementation of vaccination in those responding to our survey was high and the adverse events were comparable to the general population, with minimal impact on their IBD.
Department of Gastroenterology University Hospital of Heraklion Heraklion Greece
Department of Gastroenterology Venizeleio General Hospital Heraklion Greece
Department of Surgery DiSCOG University of Padova Padova Italy
Division of Gastroenterology Mater Dei Hospital Msida Malta
European Federation of Crohn's and Ulcerative Colitis Associations Brussels Belgium
Evangelismos Ophthalmiatreion Athinon and Polyclinic Hospitals Crete Greece
Faculty of Medicine Lisbon University Portugal
Gastroenterology Department Tzaneion General Hospital of Piraeus Piraeus Greece
Gastroenterology Division Surgical Department Hospital Beatriz Ângelo Loures Portugal
Gastrounit Hvidovre Hospital University of Copenhagen Hvidovre Denmark
IBD Center Humanitas Clinical and Research Center Milan Italy
IBD Clinical and Research Centre ISCARE Prague Czech Republic
Institute of Pharmacology 1st Faculty of Medicine Charles University Prague Czech Republic
Outpatients Department of Gastroenterology Hospital Lüneburg Lüneburg Germany
St Mark's Hospital London North West University Healthcare NHS Trust Harrow UK
Université Clermont Auvergne 3iHP Inserm U1071 M2iSH USC INRA 2018 F Clermont Ferrand France
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22024908
- 003
- CZ-PrNML
- 005
- 20221031100052.0
- 007
- ta
- 008
- 221017s2022 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1093/ecco-jcc/jjac010 $2 doi
- 035 __
- $a (PubMed)35037033
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Ellul, Pierre $u Division of Gastroenterology, Mater Dei Hospital, Msida,Malta
- 245 10
- $a Implementation and Short-term Adverse Events of Anti-SARS-CoV-2 Vaccines in Inflammatory Bowel Disease Patients: An International Web-based Survey / $c P. Ellul, J. Revés, B. Abreu, M. Chaparro, JP. Gisbert, M. Allocca, G. Fiorino, B. Barberio, F. Zingone, A. Pisani, D. Cassar, G. Michalopoulos, G. Mantzaris, I. Koutroubakis, K. Karmiris, K. Katsanos, D. Ďuricova, J. Burisch, GR. Madsen, C. Maaser, A. Naila, E. Orfanoudaki, V. Milivojevic, A. Buisson, L. Avedano, S. Leone, J. Torres
- 520 9_
- $a INTRODUCTION: Anti-SARS-CoV-2 vaccine clinical trials did not include patients with immune-mediated conditions such as inflammatory bowel disease [IBD]. We aimed to describe the implementation of anti-SARS-CoV-2 vaccination among IBD patients, patients' concerns, and the side effect profile of the anti-SARS-CoV-2 vaccines, using real-world data. METHODS: An anonymous web-based self-completed survey was distributed in 36 European countries between June and July 2021. The results of the patient characteristics, concerns, vaccination status, and side effect profile were analysed. RESULTS: In all 3272 IBD patients completed the survey, 79.6% had received at least one dose of anti-SARS-CoV-2 vaccine, and 71.7% had completed the vaccination process. Patients over 60 years old had a significantly higher rate of vaccination [p < 0.001]. Patients' main concerns before vaccination were the possibility of having worse vaccine-related adverse events due to their IBD [24.6%], an IBD flare after vaccination [21.1%], and reduced vaccine efficacy due to IBD or associated immunosuppression [17.6%]. After the first dose of the vaccine, 72.4% had local symptoms and 51.4% had systemic symptoms [five patients had non-specified thrombosis]. Adverse events were less frequent after the second dose of the vaccine and in older patients. Only a minority of the patients were hospitalised [0.3%], needed a consultation [3.6%], or had to change IBD therapy [13.4%] after anti-SARS-CoV-2 vaccination. CONCLUSIONS: Although IBD patients raised concerns about the safety and efficacy of anti-SARS-CoV-2 vaccines, the implementation of vaccination in those responding to our survey was high and the adverse events were comparable to the general population, with minimal impact on their IBD.
- 650 _2
- $a senioři $7 D000368
- 650 12
- $a COVID-19 $x prevence a kontrola $7 D000086382
- 650 12
- $a vakcíny proti COVID-19 $x škodlivé účinky $7 D000086663
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a idiopatické střevní záněty $x farmakoterapie $7 D015212
- 650 _2
- $a internet $7 D020407
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a průzkumy a dotazníky $7 D011795
- 650 _2
- $a vakcinace $x škodlivé účinky $7 D014611
- 651 _2
- $a Evropa $7 D005060
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Revés, Joana $u Gastroenterology Division, Surgical Department, Hospital Beatriz Ângelo, Loures,Portugal
- 700 1_
- $a Abreu, Bárbara $u Gastroenterology Division, Surgical Department, Hospital Beatriz Ângelo, Loures,Portugal
- 700 1_
- $a Chaparro, María $u Gastroenterology Unit, Hospital Universitario de La Princesa, IIS-IP, UAM, and Centro de CIBEREHD, Madrid,Spain $1 https://orcid.org/0000000292754242
- 700 1_
- $a Gisbert, Javier P $u Gastroenterology Unit, Hospital Universitario de La Princesa, IIS-IP, UAM, and Centro de CIBEREHD, Madrid,Spain
- 700 1_
- $a Allocca, Mariangela $u IBD Center, Humanitas Clinical and Research Center, Milan,Italy $u Department of Surgery, DiSCOG, University of Padova, Padova,Italy
- 700 1_
- $a Fiorino, Gionata $u IBD Center, Humanitas Clinical and Research Center, Milan,Italy $u Department of Surgery, DiSCOG, University of Padova, Padova,Italy $1 https://orcid.org/0000000156232968
- 700 1_
- $a Barberio, Brigida $u IBD Center, Humanitas Clinical and Research Center, Milan,Italy $u Department of Surgery, DiSCOG, University of Padova, Padova,Italy
- 700 1_
- $a Zingone, Fabiana $u IBD Center, Humanitas Clinical and Research Center, Milan,Italy $u Department of Surgery, DiSCOG, University of Padova, Padova,Italy
- 700 1_
- $a Pisani, Anthea $u Division of Gastroenterology, Mater Dei Hospital, Msida,Malta
- 700 1_
- $a Cassar, David $u Division of Gastroenterology, Mater Dei Hospital, Msida,Malta
- 700 1_
- $a Michalopoulos, George $u Gastroenterology Department Tzaneion General Hospital of Piraeus, Piraeus, Greece
- 700 1_
- $a Mantzaris, Gerassimos $u Evangelismos, Ophthalmiatreion Athinon and Polyclinic Hospitals, Crete,Greece
- 700 1_
- $a Koutroubakis, Ioannis $u Department of Gastroenterology, University Hospital of Heraklion, Heraklion,Greece
- 700 1_
- $a Karmiris, Konstantinos $u Department of Gastroenterology, Venizeleio General Hospital, Heraklion,Greece
- 700 1_
- $a Katsanos, Konstantinos $u Department of Gastroenterology and Hepatology, Division of Internal Medicine, University and Medical School of Ioannina, Ioannina,Greece
- 700 1_
- $a Ďuricova, Dana $u IBD Clinical and Research Centre, ISCARE, Prague,Czech Republic $u Institute of Pharmacology, 1st Faculty of Medicine, Charles University, Prague,Czech Republic
- 700 1_
- $a Burisch, Johan $u Gastrounit, Hvidovre Hospital, University of Copenhagen Hvidovre, Denmark $u Copenhagen Center for Inflammatory Bowel Disease in Children, Adolescents and Adults, Hvidovre Hospital, University of Copenhagen Hvidovre, Denmark
- 700 1_
- $a Madsen, Gorm Roager $u Gastrounit, Hvidovre Hospital, University of Copenhagen Hvidovre, Denmark $u Copenhagen Center for Inflammatory Bowel Disease in Children, Adolescents and Adults, Hvidovre Hospital, University of Copenhagen Hvidovre, Denmark
- 700 1_
- $a Maaser, Christian $u Outpatients Department of Gastroenterology, Hospital Lüneburg, Lüneburg,Germany
- 700 1_
- $a Naila, Arebi $u St Mark's Hospital, London North West University Healthcare NHS Trust, Harrow,UK
- 700 1_
- $a Orfanoudaki, Eleni $u Department of Gastroenterology, University Hospital of Heraklion, Heraklion,Greece
- 700 1_
- $a Milivojevic, Vladimir $u Clinic for Gastroenterology and Hepatology, Clinical Center of Serbia, School of Medicine, Belgrade,Serbia
- 700 1_
- $a Buisson, Anthony $u Université Clermont Auvergne, Inserm, CHU Clermont-Ferrand, 3iHP, Service d'Hépato-Gastro Entérologie, Clermont-Ferrand, France $u Université Clermont Auvergne, 3iHP, Inserm U1071, M2iSH, USC-INRA 2018, F-Clermont-Ferrand,France
- 700 1_
- $a Avedano, Luisa $u European Federation of Crohn's and Ulcerative Colitis Associations, Brussels, Belgium
- 700 1_
- $a Leone, Salvo $u European Federation of Crohn's and Ulcerative Colitis Associations, Brussels, Belgium
- 700 1_
- $a Torres, Joana $u Gastroenterology Division, Surgical Department, Hospital Beatriz Ângelo, Loures,Portugal $u Faculty of Medicine, Lisbon University, Portugal
- 773 0_
- $w MED00166945 $t Journal of Crohn's and colitis $x 1876-4479 $g Roč. 16, č. 7 (2022), s. 1070-1078
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/35037033 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20221017 $b ABA008
- 991 __
- $a 20221031100050 $b ABA008
- 999 __
- $a ok $b bmc $g 1854554 $s 1176198
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2022 $b 16 $c 7 $d 1070-1078 $e 2022Aug04 $i 1876-4479 $m Journal of Crohn's and colitis $n J Crohns Colitis $x MED00166945
- GRA __
- $p Portuguese Society of Gastroenterology
- GRA __
- $p CEREGA
- LZP __
- $a Pubmed-20221017
